Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Douglas Dynamics
PLOW
$976M
| $2.54M | ﹤0.01% |
46,100
+300
| +0.7% | +$15.1K |
|
2202
Merchants Bancorp
MBIN
$2.52B
| $2.53M | ﹤0.01% |
192,788
+55,875
| +41% | +$652K |
|
2203
SouthState Bank Corp
SSB
$10.8B
| $2.53M | ﹤0.01% |
29,132
-62,178
| -68% | -$5.05M |
|
|
PFSW
2204
DELISTED
PFSweb, Inc.
PFSW
| $2.53M | ﹤0.01% |
661,339
+43,100
| +7% | +$146K |
|
|
AZRE
2205
DELISTED
Azure Power Global Limited
AZRE
| $2.52M | ﹤0.01% |
200,617
+29,155
| +17% | +$369K |
|
|
DOCU
2206
DocuSign
DOCU
$11.8B
| $2.52M | ﹤0.01% |
34,000
-650,700
| -95% | -$44.7M |
|
2207
Vanguard Total World Stock ETF
VT
$81.8B
| $2.51M | ﹤0.01% |
+31,000
| New | +$2.41M |
|
|
CATC
2208
DELISTED
CAMBRIDGE BANCORP
CATC
| $2.51M | ﹤0.01% |
31,300
+18,600
| +146% | +$1.45M |
|
2209
State Street SPDR Nuveen ICE Municipal Bond ETF
TFI
$3.17B
| $2.5M | ﹤0.01% |
49,395
-40,518
| -45% | -$2.05M |
|
|
VIVS
2210
VivoSim Labs
VIVS
$1.13M
| $2.5M | ﹤0.01% |
29,266
+2,464
| +9% | +$231K |
|
2211
Westlake Corp
WLK
$10.2B
| $2.49M | ﹤0.01% |
+35,500
| New | +$2.38M |
|
2212
Celldex Therapeutics
CLDX
$3.29B
| $2.49M | ﹤0.01% |
1,115,368
+89,083
| +9% | +$207K |
|
|
SBBX
2213
DELISTED
SB One Bancorp Common Stock
SBBX
| $2.49M | ﹤0.01% |
99,800
-13,500
| -12% | -$312K |
|
2214
Mitek Systems
MITK
$877M
| $2.48M | ﹤0.01% |
324,176
+212,887
| +191% | +$1.8M |
|
|
HCR
2215
DELISTED
Hi-Crush Inc. Common Stock
HCR
| $2.48M | ﹤0.01% |
2,807,387
+1,325,603
| +89% | +$1.4M |
|
2216
ProShares Ultra S&P500
SSO
$8.47B
| $2.47M | ﹤0.01% |
+131,200
| New | +$2.26M |
|
2217
Ingles Markets
IMKTA
$1.65B
| $2.47M | ﹤0.01% |
52,000
+15,500
| +42% | +$660K |
|
2218
Biglari Holdings Class B
BH
$1.21B
| $2.47M | ﹤0.01% |
21,576
-2,750
| -11% | -$280K |
|
2219
Midland States Bancorp
MSBI
$693M
| $2.46M | ﹤0.01% |
84,800
+3,800
| +5% | +$105K |
|
2220
Landmark Bancorp
LARK
$196M
| $2.45M | ﹤0.01% |
131,262
+10,402
| +9% | +$179K |
|
|
XOMA
2221
DELISTED
Xoma
XOMA
| $2.45M | ﹤0.01% |
+89,733
| New | +$2.01M |
|
|
PVG
2222
DELISTED
PRETIUM RESOURCES INC.
PVG
| $2.45M | ﹤0.01% |
220,044
-946,355
| -81% | -$10.1M |
|
2223
Vanguard Global ex-US Real Estate ETF
VNQI
$3.51B
| $2.45M | ﹤0.01% |
+41,388
| New | +$2.48M |
|
2224
Equitable Holdings
EQH
$14.5B
| $2.44M | ﹤0.01% |
98,500
-1,052,100
| -91% | -$24.4M |
|
|
SMED
2225
DELISTED
Sharps Compliance Corp
SMED
| $2.44M | ﹤0.01% |
576,902
+91,958
| +19% | +$395K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.